Trial Profile
An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 18 Feb 2020 Status changed from active, no longer recruiting to completed.
- 06 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2019 Planned End Date changed from 1 Dec 2019 to 31 Jan 2020.